# A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia

> **NCT04102501** · PHASE3 · COMPLETED · sponsor: **Biojiva LLC** · enrollment: 65 (actual)

## Conditions studied

- Friedreich's Ataxia

## Interventions

- **DRUG:** RT001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04102501
- **Lead sponsor:** Biojiva LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-30
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-08-23
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2022-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102501, "A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04102501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*